Supplementary information for

Cell-free expression of functional receptor tyrosine kinases

Wei He, Tiffany Scharadin, Matthew Saldana, Candice Gellner, Steven Hoang-Phou, Christina Takanishi, Gregory L Hura, John A Tainer, Kermit L. Carraway III, Paul T. Henderson, Matthew A. Coleman

This file includes:

Supplementary Figures 1 – 7

Supplementary Tables 1 – 2

Supplementary Figures	3
Supplementary Tables	13

Supplementary Figure 1



Fluorescent image of denaturing SDS PAGE of cell-free expressed Δ49A1 and ERBB2. Cell-free expressions were set up using the Expressway Maxi Cell-Free *E. coli* Expression System from Life Technologies according to manufacturer's user manual. Reactions were set up with: no DNA, DNA encoding ERBB2 only, DMPC and DNA encoding ERBB2, DMPC and DNA encoding Δ49A1 (empty NLPs), DMPC and DNA encoding both ERBB2 and Δ49A1 (ERBB2-NLPs). FluoroTect[™] GreenLys (Promega) was added for visualizing synthesized protein. Reactions were ended after 18 hours by adding LDS sample buffer from Life Technologies. All samples were boiled for 5mins and resolved by 4-12% SDS-PAGE along with a molecular weight standard (M). Gel images were taken using Molecular Dynamics Typhoon 9410 Molecular Imager from GE Healthcare.



Western blot shows ERBB2-NLP can be Ni purified. Set up 1mL cell-free expression reaction to produce ERBB2-NLP as described in Methods. After 18 hours reaction, a small aliquot of crude was saved as total (T). The rest of the crude mixture was collected and incubated with 0.5 mL Ni-NTA SuperFlow resin (Qiagen) at 4 degree for 2 hours; the unbound crude was collected as flow through (F). Ni resin was then washed with 6mL wash buffer containing increasing concentration (10mM, 20mM, 50mM, two of each, 6 mL total) of imidazole (Wash, 1mLx6). The bound protein was then eluted with 1mL elution buffer containing 400mM imidazole for 6 times (Elution, 1mLx6). Elutions were combined and dialyzed against 1L of TBS, twice; then concentrated with Vivaspin column MWCO=100kDa (C). Final volume is 300uL. Samples were then resolved by SDS-PAGE and western blotting with anti-ERBB2 antibody Ab-3.

4



Cell-free expressed ERBB2-NLP and YopD-NLP (Bodipy labeled) were bound to Ni beads through a 6xHis tag located on the scaffold protein Δ49A1. The Ni beads were washed with buffer containing 20mM imidazole, and then eluted with 100 mM sodium carbonate, or 400mM imidazole. The eluents were concentrated and resolved by SDS-PAGE. Pictures of the gel were taken with GE Typhoon 9410 fluorescent imager Ext/Emt: 488 nm/520 nm (a). 48% of YopD protein can be carbonate extracted, whereas only 3% of ERBB2 protein can be carbonate extracted (b).



Small angle X-ray scattering (SAXS) data for ERBB2-NLPs that were prepared by cell-free expression comparing with empty NLP. NLP and ERBB2 NLP samples were cell-free produced and Ni purified as described. Each sample consisted of 20 microliters of 0.23 mg/ml of total protein. There was a clear difference in the spectra of the NLP with ERBB2 incorporation indicating a 2-fold or more increase in thickness of the nanoparticles compared to the empty NLPs.



Full-length versions of gel image presented in figure 1

ERBB2 was cell-free produced in the presence and absence of DMPC or with DMPC and co-expressed ∆49A1. FluoroTect[™] GreenLys (Promega) was added for visualizing newly synthesized ERBB2 protein. After 4 hours of expression, cell-free reactions were centrifuged at 14,000 rpm for 10 minutes. Small aliquots of sample before centrifuging (total, T), the supernatant (soluble, S) and pellet (P) after centrifuging were collected. All samples were loaded along with a cell-free reaction mixture only (-). Gel images were taken using Molecular Dynamics Typhoon 9410 Molecular Imager from GE Healthcare.

a α-Phospho-ERBB2

(-) 2h 5h 8h 18h



b α-ERBB2

(-) 2h 5h 8h 18h



C α-Phospho-ERBB2



e _{α-EGFR}

f



Full-length versions of western blots presented in figure 2

NLP associated ERBB2 is tyrosine phosphorylated. Cell-free expressions were set up with and without (-) ERBB2 plasmid. Samples were collected at 2hr, 5hr, 8hr and overnight 18hr and resolved by SDS-PAGE and western blotting with anti-phospho-tyrosine ERBB2 antibody pY1248 (a) and anti-ERBB2 antibody Ab-3 (b) after stripping.

The NLP associated ERBB2 is phosphorylated independent of protein expression. Cell free expressed ERBB2 is treated with calf-intestinal alkaline phosphatase (CIP) and Ni purified. The purified ERBB2-NLPs are then incubated with ATP, Mn²⁺, Mg²⁺ and buffer to allow for re-phosphorylation. Samples are resolved by SDS_PAGE and western blotting with anti-phospho-tyrosine antibody 4G10 (c) and anti-ERBB2 antibody Ab-3 (d).

NLP associated EGFR is also phosphorylated. Presence of EGF in the cell free reaction increases the level of phosphorylation. EGFR-NLPs showed low level of phosphorylation during cell-free expression. Adding EGF, the natural ligand of EGFR, increases the phosphorylation. Cell-free expressions were set up with and without (-) EGFR plasmid, with and without EGF. After 8hrs reaction, cell-free mixtures were resolved by SDS-PAGE and western blotting with anti-EGFR (e) comparing to western blotting with antiphospho-tyrosine EGFR antibody pY1110 (f).

Supplementary Figure 7.

Alignment of the DNA sequences of human ERBB2 and EGFR genes with the DNA sequences that were codon optimized for *E.coli* expression. A dark block represents where the two sequences share the same base.

DNA encoding human ERBB2: comparing E.coli codon optmized sequence to human gene sequence.

E.coli Human	AT GGA <mark>AT</mark> T GGC <mark>AT T G T GT GT GGGGGT T T GT T GT T GT </mark>	101 101
E.coli	GGGT <mark>CCCTGG TTCC</mark> CC <mark>AGAAACCCACCTCGATATGTTG</mark> CGCCCA <mark>T</mark> CTCTATCAAGGGTGCCA <mark>A</mark> GTGGTGCAGGGTAATCCGGAACTGACCTACCTGCCTAC	201
Human	GGGT <mark>C</mark> CCTGC <mark>CAGTCCCGAGACCCACCTGGACATGCTC</mark> CGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAACTCCACCTGCCCACCCGAC	201
E.coli	GAAGGGTTGCCTGAGCTTTCTGCAAGATATCCAAGAAGTGCCAGGGCTACGTTCTGATTGCCCACAACCAGGTCCGGCAGGTCCCGTTGCAGCGGCTGCGC	301
Human	GAATGGCAGCCTGTCCTTGCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGCAGGCCGCACGACGAGAGGCCGGG	301
E.coli	ATT GT TCC G GC ALCCCAG CT CT T CGAGGA TAAC TAC GCC T GGC GT GCT GGATAAT GGT GALCCG T TGAA CAA TACCAC GCC GGT GALCTAG T GGT GCT T C C C	401
Human	ATT GT G C C A GC C A C C C A G C T C T T T G A G A C T A T G C C G T G G C G T G C A C A G G A G A C A C A C A C A C A	401
E.coli	CCGGAAGC <mark>ACTCCCCGGAACTGCAGCTGCGGAGCCTGACCGAAAATTC</mark> TGAAAGGGAGCGTGCTGATTCAACG <mark>AACCCT</mark> CAGCTGTGCTACCAGGACACTAT	501
Human	C <mark>A</mark> GGAGC <mark>C</mark> CTCCCCGGAGCTGCAGCTTCGAAAGCCTCACAGAACCTGAAAGGAGGGTCTTGATCCAGCGGAACCCCCCAGCTCTGCTACCAGGACACCAA	501
E.coli	CTTGTGGAAGGACATCTTTCACAAGAACAACCAGCT <mark>C</mark> GCGCTCACGCTGATTGACACCAATCGCAGCCGTGCCTGTCACCCTTTG <mark>CAGCCCT</mark> ATGTGCAAA	601
Human	TTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCTCTCACACACTGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTCTCCCGATGTGTAAG	601
E.coli	GGCTCCCGCTCTTGGGGGTGA <mark>A TCCAGCGAGGATTGC</mark> CAG <mark>TCT</mark> CTGACGCGCACGGGTCTG <mark>C</mark> GGCAGGCGGCGGTGCCGCTGCAAAGGGTCCGCTGCCGACCG	701
Human	GGCTCCCGCTCCCGCTGCAAGAGAGTTCTGAGGATTGTCAG <mark>AGC</mark> CTGACGCGCACTGTCTGTGCCGGTGGCTGTGCCCGCTGCAAAGGGGCCACTGCCCCCCCC	701
E.coli	ACTG <mark>T</mark> TGCCATGAGCAGTGC <mark>GCGAGCGGGTTGCACGGGTCC</mark> AAAGCACTCTGACTGCCTGGC <mark>ATGTCTCCACTTCAACCAC</mark> TCTGGCAT <mark>TTGC</mark> GAGCTGCA	801
Human	ACTG <mark>C</mark> TGCCATGAGCAGTG <mark>TGCTGCC</mark> GG <mark>C</mark> TGCACGGG <mark>C</mark> CC <mark>C</mark> AAGCACTCTGACTGCCTGGCCTGCCACTTCAACCAC <mark>AG</mark> TGGCAT <mark>C</mark> TGGCATGTGAGCTGCA	801
E.coli	CTGCCCTGCCCTGGTTACGTACAACACTGACACTTTGGAGAGCCATGCCAAAATCCGGAAGGGCGCGTATACCTTGGGAGGGCGCTCTTGCGTGACGGCATGTCCA	901
Human	CTGCCCAGCCTGGTGACGCACCACACACACAGACACGTTTGAGTGCATGCCAAGCCGCAATCCGGAGGGCCGGTATACATTGGGCGCCGGCAGCTGTGGACTGCCTGC	901
E.coli Human	ŦĂĊĂĂĊŦĂĊĊŦĊĊŢĊŦĂĊĊĠĂŢĠŦĠĠĠĊŦĠŢĂĊĠĊŦĠĠŦĊŦĠĊĊŢĊŦĠĊĊŢĊŦĠĊĂŢĂĂĊĊĂĠĠĂĂĠŢŢĂĊŢĠĊĠĂĠĠĂĊĠĊĊĊĊĊĊĊĊĊĊ	1001 1001
E.coli	ĞTTCTĂĂĂĊĊĊĂŦĞTĞCĞĊĞTĞTĞĊĊŦŦĞĞĊŢTĞĞĞCĂTĞĞAĂĊĂŢĊŢĞĊĞĞAĂĞTĞĊĞŢĞĊĞĞĞĞĂĞĞŢĞĂĊĊĂĞĞĞĂĂĂĊĂŢŢĊĂĂĞĂĞTTŢĞĊĞĞĊŦĞ	1101
Human	ĞĊĂĞĊĂĂĞĊĊĊŢĞTĞÇĊĞĂĞTĞTĞĊTĂTĞĞŢĊŢĞĞĞCĂTĞĞĂĞĊĂĊŢŢĞĊĞĂĞĞĞĞ <mark>AĞĞŢĞĂĞĞĞĊĂ</mark> ĞŢŢĂĊĊAĞŢĞĊĊĂĞĂŢĂŢĊĊĂĞĞAĞTTTĞĊŢĞĞĊŢĞ	1101
E.coli	ŢĂĂĞĂĂ <mark>ĂĂŦĊŦŢĊ</mark> ĠĞ <mark>ŢŢĊ</mark> ĊĊŢĠĊĊĠŢŢĊĊŢĠĊĊĠĠĂĞŢĊŢŢŢŢŢĠĂŢĠĊŢĠĊŢĂĠĊĂĂŢĂĊĊĠĊĂĊĊĊĊŢŎĊĂŎĊĊĂĠĂĠĊĂĠĊŢĠĊĂĂĠŢŢŢŢĊ	1201
Human	ĊĂĂĞĂĂ <mark>Ċ</mark> ĂŢĊŢŢŢĠġ <mark>ĠĂĞĊĊŢĠĠĊ</mark> ĂŢŢŢĊŢĠĊĊĠĠĂĞ <mark>ĂĠĊ</mark> ŢŢŢĠĂŢġĠ <mark>ġŎġĊĊĊ</mark> ĂĠĊĊŢĊĊĂĂĊŔĊŢĠĊ <mark>Ċ</mark> ĊĊĠĊŢ <mark>Ċ</mark> ĊĂŎġĊĂġĊĊŢĊĊĂĂĠŢŎŢŢŢ	1201
E.coli Human	GAAAAG <mark>C</mark> CT GGAAGAGA T TA C TGG T TACC TC TACAT C T C GGG C T GGCCGGAC AGCCT GCCT	1301 1301
E.coli Human	GCATTCTCCACAATGGCGCCTA <mark>TAGCCTGACTCTGCAG</mark> GGCCTGGGGCATTTCCTGGGCTGGG	1401 1401
E.coli	ĊĂŢĊĊĂŢĊĂĊĂĂĊĂŔĊĂŢĊĂŢĊŢĠŢĠĊŢŢŢĠŢĠĊĂĊĂŢĠŢĠĊĊŢŢŦĠĠĠĂŢĊĂĠĊŢĠŢŢŢĊĠĊĂĂŢĊĊĠĊĂĊĊĂĠĊĠĊŢĊĂĊĊĊĊŢ	1501
Human	ĊĂŢĊĊĂĊĊĂŢĂĂĊĂĊĊĊĊĊŢĊŢĠĊŢŢĠĊĬĊĊĠĠŢĠĊĊĊĊŎġĠġŎĸĊĊĂġĊĊŎŢŢŢĊĠĠĂĂĊĊĊġĊĂĊĊŎĊŎĊŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎ	1501
E.coli	GAGGACGA <mark>ATCC</mark> GTCGGTGA <mark>A</mark> GGTCTGGCGTGCCATCAGCTCTCTGTGCGTCACTGTTGGGGACCGGGTCCAACGCAACGCGAATGCGTCAATTGCTCCCAGT	1601
Human	GAGGACGACGACGAGGGCGAGGGCCTGGCCT	1601
E.coli Human	TICTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	1701 1701
E.coli Human	TCA <mark>A</mark> CCA <mark>ACAAAAC</mark> GGTAGCGTTACGTGTTTCGGGCCTGAGGCTGATCAATGCGTTGCTTGC	1801 1801
E.coli	CCAAGCGGGGTCAAGCCGGATCTGAGCTATATGCCTATCTGGAAATTCCCGGATGAAGAGGGGGGCTTGTCAGCCATGTCCGATCAATTGCACCCACAGCT	1901
Human	CCCAGCGGTGTGAAACCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAGGGCGCATGCCAGCCTTGCCCCATCAACTGCACCCACTCCT	1901
E.coli	GCGTTGACCTCGATGATAAAGGCTGTCCAGCCGAGCAGCGGGGGGAAGCCCTCTCACCAGCATCATTAGCGCAGGTGGGGGAATTCTGCTGGTGGTGGTCGTTTT	2001
Human	GTGTGGACCTCGATGACAAGGGCTGCCCCGCGAGCAGAGAAGAGCCCTCTGACGTCCATCATCTCTGCGGTGGTGGTGGTGGTCGTCGTCGTCGTCGTCGT	2001
E.coli	GGGTGTTGTGTTTGGTATCCTGATCAAACGCCGCCAACAAAAAATCCGCAAGTACACCATGCGTCGCCTGTTGCAAGAAACCGAGTTGGTGGAGCCGCTG	2101
Human	GGGCGTCGTCTTTGGGATCCTCAAGCGACGGCAGCAGCAGAAGATCCGCAAGTACACGATGCGGAGACTGCTGCAGGAAAACGGAAGCCGCTG	2101
E.coli Human	ACTCCATCTGGCGCGATGCCTAATCAAGCCCAGATGCGCATTTTGAAAAGAGACTGAGCTGCGCAAAGTTAAAGGTGCTGGGGAGGGGGGGG	2201 2201
E.coli Human	ΤΗΤ Α C Α Α Α Ο G T A T T T G G A T T C C G G A C G G T G A G A A C G C G C G C G C G C A T C A A A G C C G C A A A A C A C T G C G C A A A A G C C G C A A A A C A C	2301 2301
E.coli	ŦĊŦĔĠĂŢĠĂĊĠĊĊŦĂŢĠŦĠĂŦĠĠĊĊĠĠŦĠŦĠĠĠġĂĠĊĊĊŢŦĂĊĠŦĠĂĠĊĊĠŦĊŦĊĊĠĊĊŦĊŦĠĊĊŦĠĊĊŢĂĊĠġŦĊŢĂĊĠġŦġĊĂĠŢŦĠĠŦġĊŔĊĊĂĂĊŦġ	2401
Human	ĊŦŢĂĠĂĊĠĂĂġĊĂŦĂĊġŦġĂŦġġĊŢġġŦġŦġġġĊŦĊĊĊĊĊĂŢĂŢġŢĊŦĊĊĊĠĊĊŦŢĊŢĠġġĊĂŦĊŦġĊĊŦġĊĊŢĂĊĊŎĊŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎŎ	2401
E.coli	ĂT GCC <mark>C</mark> TĂ <mark>GGCT</mark> T GCCTGTTGGA CCATGTTCGTGAAAACCCTGGCCGCTGGGGAGCCAGGATCTGCTGAATTGGTGTATATGCAGATTGC	2501
Human	AT GCC <mark>C</mark> TĂ <mark>GGCTGCCTCTTA</mark> GA CCATGT <mark>C</mark> CG <mark>GGAAAACCCCGGGACGCTGGGCTCCCAGGACCTGCTGAAC</mark> CTGGTGTATATGCAGATTGCCAAAGGGATGA	2501
E.coli	CTATCTGGAAGATGTCCGCCTGGTTCATCGCGATCFGGCAGGCCGGAAGGTCCGGAAATCCCCGAATCCCCGAATCAAGATTACTGATTTGGTCTGGC	2601
Human	CCTACCTGGAGGATGTGCGGCTCGTACACAGGGACTTGGCGGCCGGAAGGTGCTGGTCAAGAGTCCCGAAGCATGTCAAAAATTACAGATTACGGGCTGGC	2601
E.coli	CCCCTTOCTOGACATCGACGACGACTGAATATCATGCGGACGGCGGGCAAAGTCCCGATCAAGTGGATGGCCCTOGAAAGCATTCTCCGCCGTCGCTTCACC	2701
Human	TCCGCTGCTGCACATTGACGAGACAGGGTACCATGCAGATGCCGGCGAGCAAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCCTTCACCGCCGCGCTCACC	2701
E.coli	ĊĂŢĊĂĠĂĞ <mark>Ġ</mark> ĠĂ <mark>ĠŦĠŦĠĠŦĊĊ</mark> ŦĂŦĠĠ <mark>ĊĠŦĠĂĊĠĠŦŢ</mark> ŦĠĠĠĂĠĊŦĠĂŦĠĂĊĠŦŤĊĠĠĊĠĊĠĂĂĂĊĊĂŢĂĊĠĂ <mark>Ċ</mark> ĠĊ <mark>Ġ</mark> ĊĂŦĊĊĊŢĠĔĊĠĊĠĂĠĂĊŢĊĊ <mark>Ă</mark> ĠĂĊĊ	2801
Human	ĊĂ <mark>Ċ</mark> ĊĂĠĂĊ <mark>Ŧ</mark> ĠĂŢĠŦĠŦĠĠ <mark>ĂĠŢŦĂŦĠġŢĠŦĠĂĊŢĠŢ</mark> ĠŦĠĠĠĂĠĊŦĠĂŦĠĂĊĊŦŤŦŢĠĠĠĊĊĂĂĂĊĊŢŦĂĊĠĂŢĠĠĠĂŦĊĊĊ <mark>Ă</mark> ĠĊĊĊĠĠĠĂĞĂŤ <mark>Ċ</mark> ĊĊŢĠĂĊĊ	2801
E.coli	ŦĠĊŦĠĠĂ <mark>Ċ</mark> ĂĂĞĞĞ <mark>ĂĞĂĂĊĠĊĊŦĠĊĊŢĊĊĠĊĊŢĂŦĊŦĠĊĂĞĊ</mark> ĂŦŦĞĂ <mark>ĊĞŦĊŦĂŢĂŦĠĂŢĬĂŦĠĂŢĬĂĂĞŢĠ</mark> ŢĠĠĂŦĠĂŢ <mark>ĊĠĬŦĠĊĊĠŢĊĊ</mark>	2901
Human	ŦĠĊŦĠĠĂ <mark>ĂĂĂĠĠĊĠĸŎĊĠĊŦĠĊĊĊĊĊĸĠĊĊĊĊ</mark> ĂŦĊŦĠĊĂĊŢĠĂŢŦĠĂŢĠŦĊŦĂ <mark>ĊĂŦĠĂŢĊĸŦĠĔŢĊŔŎ</mark> ĬŢŎĠĂŢĠŎŢŢĠĠĂŢĠŢĊĊĊŢŎĂ	2901
E.coli	GCCGTTTCCCGGAATTGGTTAGCGAGGTTCAGCCGGATGGCGGCTGACCCGCAGCGCTTCGTCGTTATCCAGAATGAGGATCTGGGGGCCAGCGAGCCGGCTG	3001
Human	AAGATTCCCCGGAGTTGGTGTCTGAATTCTCCCGCATGGCCAGCGACCCCCCGCAGCGCTTTGTGGGTCATCCAGAATGAGGACTTGGGGCCAGCGCAGCCGCTTG	3001
E.coli	GA <mark>T</mark> AGCACCTTT <mark>T</mark> ACCGC <mark>AGC</mark> CTGCTGGAGGACGATGACATGGG ^G GACCTGGTGGATGC <mark>GGAA</mark> GAGTACCT <mark>G</mark> GT <mark>G</mark> CC <mark>T</mark> CAGCAGGGGCTTCTTCTGTCCAG	3101
Human	GA <mark>C</mark> AGCACCTT <mark>C</mark> TACCGC <mark>TCA</mark> CTGCTGGAGGACGATGACATGGG ^G GACCTGGTGGATGCTGAGGGAGTATCCG ^G CAGCAGGGCTTCTTCTGTCCAG	3101
E.coli	ACCC <mark>A</mark> GCCCCTGGGCGCAGGGGGTATGGTTCACCACCGCCATCCTTCTAGCTCTACCGTAGCGGTGGTGGTGGGACCTGGGCCCTGGAACCGAGCGA	3201
Human	ACCCTGCCCCCGGGCGCAGGGGCATGGTCCACCACAGCAGGAGTGGCGGTGGCGGTGGCGACCCTGAACAGGAGCGCCCCCCCGA	3201
E.coli	AGA <mark>A</mark> GAGGG <mark>ACCACGTAGCCCACTCGCCCCTTCTGAGGGTGGCGGGGGGTAGCGATGTGTTTGACGGGGACTTGGGAATGGGGGCAGCCAAGGGCCTCCAGTCC</mark>	3301
Human	AGA <mark>CGAGGCCCCCACGTAGCCCACTGCCACCGCAAGGGCTGC</mark> GGTGGCTGCGATGT <mark>ATTTGATGGTGACC</mark> TGGGAATGGGGCAGCCAAGGG <mark>GCTGCAAAG</mark> C	3301
E.coli	ĊŢ <mark>ĊĊĊ</mark> ĂĂĞ <mark>Ċ</mark> ĊĂŢĠĂĊĊĊŢĊĊĊĊĊŢĠĊĂĊĊŢĂŢŢĊĊĠĂŔĠĂŢĊĊĠĂĊĊĠŢĊĊĊĂŢŢĠĊŢĂĠĊĊŔŎŢĠĊĊĂĊŢĠĊĊĊĊĊŢĠĊĊĊĊŢŢĊĊĊĊĊŢĠĊĊĊĊŢŎĊĊĊŢŢŢ	3401
Human	ĊŢ <mark>ĊĊĊ</mark> ĂĊĂĊĂŢĠĂĊĊĊĊĊŢŎĊĊĊĊŢĂĊĂĠĊĠĠŢĂĊĂĠŢĠĂĊĊĊĊĊĊĊĊĊĊ	3401
E.coli	CTCCACAGCCAGAATATGTGAATCAGCCTGACGTGCGCCGCCACAAACGGCCTAGCCCTCGTGAGGGGCCTCTGCCAGCTCGCCCCGAGGCGCCACTCT	3501
Human	GCCCCCAGCCTGAATATGTGAA <mark>CCAGCCAGATGTTCGGCCCCCAAGAGGCCCCTCGCGAGAGGGC</mark> CCTCTGCCTGCTGCCACGCCAC	3501
E.coli	ġġĂġġġŢĊĊ <mark>Ă</mark> ĂĂġġĊĊĊ <mark>Ă</mark> ĂĂġġĊĊĊ <mark>ġ</mark> ġġŢĂĂġĂĂŢġġĊĊ <mark>ġ</mark> ġŢĊĂĂĂġĂĊġŢŢŢŢġġġġġĊ <mark>ġ</mark> ġŢĊĊĂĂġġġġŢŎĊŢĊĂġ	3601
Human	ġġĂ <mark>ĂĂġ</mark> ġĊĊĊĂĂġĂĊ <mark>ŦĊŢĊŢĊĊĊĂ</mark> ġġ <mark>ĂĂġĂĂŢġġ</mark> ġŢĊĂĂĂġĂĊġŢŢŢŢŢġġġġġŢġĊĊŎĬġġġġŢĊĊĊĂġġġġŢŎĊĊĊĂġ	3601
E.coli Human	GGTGGTGGAGGTCCACAGCGACACCCGCCTCCAGCGTTCAGCCCAGCGTTCGATAATCTGTATTACTGGGATCAGGACCCGCCAGAGCGGGGGGGG	3701 3701
E.coli	CAAGCACCTTCAAGGGCACCCCAACCGCAGAGAACCCTGAATATCTGGGTTTGGACGTTCCGGTGTGA	3769
Human	CCAGCACCTTCAAAGGGACACCTACGGCAGAGAACCCAGAGTAGCTGGGTCTGGACGTGCCAGTGCGA	3769

DNA encoding human EGFR: comparing E.coli codon optmized sequence to human gene sequence.

Human E.coli CCAGCAATAAGCTGACTCAACTGGGCACCTTTGAGGACCACTTTCTGTCTCTGCAACGTATGTTCAACAACGGAGGTGGTTCTGGGTAATCTGGGGTAATCTGGGAAAT CCAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGCATGTTCAATAACTGTGAGGTGGTCCTTGGCAATTTGGAAAT 201 Human E.coli A C C T A <mark>C</mark> G T T C A A C G T A C G A C C T G A G C T T C C T G A A A A C C A T T C A G G A A G T G G C C G G C T A C G T T C T G A T A C T G T G C T G G A A C G T A T A C C T A T G T C C A G A C G A A T T A T G A T C T T T C C T T C T T A A A G A C C A T G C C A G A C G T G G C T A C C T A T G T C C A G A C G A A T T A T G A T C T T T C C T T C T T A A A G A C C A T G C C A G A C G T G G T T A T G C T C A C G T T A T G C T C A A C A C A C A C A G A C A A T A C T G C A A G A C A A T A C T Human E.coli 401 401 Huma E.coli 501 501 Human E.colii CGTTTCTTCGGACTTTCTGAGCAAA TA TG<mark>AGC</mark>A TGGACTTCCA<mark>A</mark>AACCACCTGGGCAGCTG<mark>T</mark>CAAAAGTGTGA TCCAAGCTGTCC AGTCAGCAGTGACTTTCTGAGCAACA TGTCGA TGGACTTCCACAACCACCTGGGCAGCTGCCAAAAGTGTGA TCCAAGC TGTCCC 601 601 Human E.coli 701 701 Human E.coli 801 801 Human 901 901 E.coli GAT GCT GT A C A A C C C GA C C A C G T A T C A A T GG A <mark>C</mark> GT T A A T C C G G A G G GT A A GT A G C T T T G G T G C G A C C T G T G T C A A G A A A T GT C C C C G T A A T A T C A T GCT GT A C A A C C C G A C C A C G T A G C A G A T GT G A A C C C G G A G G G G G A A A T A G A GCT T T G G T G C G A C C T G G T G A A G A A G A G T GT C C C C G T A A T T A CGTG Human E.coli 3 A C C G A C C A T G G T A G C T G T G T C C G C G C G T G C G G G T G C G G A T A G C T A C G A G A T G G C G T T C G T A A A T G C A A G A A T 3 A C A G A T C A C G G C T C G T G C G T C C G A G C T G T G G G G C G G A C G C C T A T G A G A G A G T G T A G Human 1001 E.colii 110 ACCACCATCTCCGG ACCTCCATCAGTGG 1201 1201 E.coli Human 1301 1301 E.coli Hume 1401 1401 E.coli Human E.coli A A T<mark>C</mark>T GT GC T A <mark>C</mark>G A <mark>C</mark>A A <mark>C</mark>A A C T GG A A<mark>G</mark> A A <mark>G</mark> C T GT T T G C A C GG G C C GG T C A G A A A A C GA A GA T T A T A A C A A C A GT G G T G A G A A A A C A GC T G A A TH T GT GC T A H GC A A T A A A C T GG A A A A A A C T GT T T G C A C C T C C GG T C A G A A A A C GA A A A T A T A A C A A C A GA GT GA A A A C A GC T G 150 Human 1500 1601 1601 Ecoli TCGTG E.coli Human 170 E.coli 1801 Huma E.coli A C A A<mark>T</mark> A C T C T G G T G G A A<mark>A</mark> T A C G C <mark>G G A C G C G G G T C A C G T C</mark> G T C C C C C C T G T G T C A T C C G A A T T G C A C T T A T G G T T G C A C A A G A C C T G G T G T G G A A G T A C G C A G G C C C A G T C T G C C A C C T G T G C C A T C C A A A G T G C A C C T A C G G A T G C Human 2001 E.coli Human 2101 2101 E.coli Human 2201 E.colii Human E colli E.coli 2401 2401 Human E coli 250 250 C T G G C T C G C A A C G T <mark>G</mark> C T G G T T A A A A C <mark>G C C A</mark>C A G C A C G C C A G A T C A C <mark>G G T T T T G G C</mark> C T G G C G C T G G C A G G C A G G A A C G T A C T G G T G A A A A C C C C C A G C A T C A C A G A T C A C A G A T T T T G G C T G G C A G G C A G G A A C G T A C T G G T G A A A A C C C C C A G C A T C A C A G A T C A C A G A T T T T G G Human 270 E.coli Hume E.coli GG<mark>C</mark>GT<mark>C</mark>ACCGT<mark>G</mark>TGGGAGC<mark>TGATGACTTTG</mark>GGTAGCAA<mark>ACCGTACGACGGTATTCCG</mark>GCCAGCGAGATTCCC<mark>AG</mark>CAT<mark>T</mark>CTGGAGAAAGGCGA GGCGTCACCGTTTGGGAGATGATGACGTTTGGACGATGCCAAGCCATGTGACGGAATCCCTGCCAGCGAGATGTCCTCCATGCTGGAGAAAGGAGA GC 2801 2801 E.coli 2901 2901 Human 3001 3001 E colli GGA TA TGGA CGA CG T CG TGGA T G CGGA CGA A T A C C T G A T C C C G C A G C A T T C T T C T T C T T C C C C G A G C A G A CA TGGA CGA CG T G G T G G A T G C C G A C G A G T A C C T C A T C C C A C A G C A G C C C T C C C C C C C E.coli CCCC Human 31.0 E.coli A A T<mark>A G</mark>C A C<mark>T</mark> GTT GC <mark>A T G C A T T G A T C G C A A C</mark> G GT C T G C A A A G C T G<mark>C</mark> C C A A T C A A <mark>A</mark> G A A G A A A TTCC A C C GT C G C T T G C A T T G A T A C A A A T G C C C T G C A A A G C T GT C C C A T C A A G G A A G A 3201 Human E.coli GCGTTATAGCAGCGACCCGACCCGACCGGTGCACTGACGGAGGATTCTATCGACGACACGTTTTTGCCGGGTTCCGGAATACATTAATCAAAGCGTGCCG GCGATACAGCTCAGACCCCCACAGGCGCCTTGACTGAGGACAGCATAGACGACACCTTCCTCCCCAGTGCCTGAATACATAAACCAGTCCGTTCCC 3301 3301 Human 3401 3401 E.colli Human E.coli GCAATCCGGAATATCTGAACACCGTGCAGCCGACCTGCGTCAATAGCACGTTCGATTCTCCGGCGCACTGGGCCCAAAAGGGTTCTCACCAGATTAGCCT GCAACCCCGAGTATCTCAACACTGTGCCAGCCGACCTGTGTCAACAGCACATTCGACAGCCCTGCGCCACTGGGCCCAGAAAGGGCAGCCAAATTAGCCT 3501 3501 Human 3601 3601 E.coli GGACAACCC<mark>C</mark>GACTATCA<mark>A</mark>CAGGACTTTTTCCCGAAAGGCCTAAGCCGAATGGCATCTTCAAGGGGTAGCACCCGAGAATGCGGGACTACCTGCGTGTT GGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAAGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC Human GCACCGCAGAGCAGCGAGTTCATCGGTGCCTAA GCGCCACAAAGCAGTGAATTTATTGGAGCATGA 3634 3634 E.coli

Supplementary Tables

Supplementary Table 1. List of genes and plasmids.

Plasmid	Vector	Gene	Tag	Resistance
pJexpress 414- EGFR	pJexpress 414	EGFR *	None	Amp
pJexpress 414- ERBB2	pJexpress 414	ERBB2 *	None	Amp
pIVEX-Δ49A1	pIVEX2.4b	Δ49A1	6xHis	Amp

pJexpress 414 is from DNA2.0; pIVEX2.4b is from Roche.

• Genes are codon optimized for *E.coli* expression. For sequence details see Supplementary Figure 7.

Supplementary Table 2. List of antibodies.

Antibody name	Target	Host	Comp.	Clone	Dilution
Anti-c-ErbB2/c-Neu (Ab-3)	hERBB2, C terminal	Mouse	EMD	mAb	1:1000
p-Tyr Antibody (4G10)	phosphotyrosine	Mouse	EMD	mAb	1:1000
Phospho-ErbB2 (Tyr1248) Antibody	hERBB2, phosphor-tyrosine at 1248	Rabbit	Assay Biotech	pAb	1:1000
Trastuzumab	hERBB2, juxtamembrane	Humanized	Genentech	mAb	N/A
EGFR Antibody (1005)	hEGFR, C terminal	Rabbit	Santa Cruz	pAb	1:1000
Phospho-EGF Receptor (Tyr1110) Antibody	hEGFR, phosphor-tyrosine at 1110	Rabbit	Assay Biotech	pAb	1:1000